Methimazole (Tapazole) FAERS Safety Signals: What Post-Market Surveillance Reveals

What FAERS Is and Why It Matters for Methimazole

The FDA Adverse Event Reporting System (FAERS) is a pharmacovigilance database that collects voluntary reports from patients, caregivers, and healthcare providers, as well as mandatory reports from drug manufacturers. As of 2024, FAERS holds more than 25 million individual case safety reports across all drugs, making it the largest spontaneous-reporting database in the United States.

For methimazole specifically, FAERS serves as the primary real-world lens through which regulators track rare harms that clinical trials, which typically enroll a few hundred to a few thousand patients, cannot reliably detect. Methimazole has been on the U.S. Market since 1950, giving FAERS decades of accumulating signal data.

How Signal Detection Works

The FDA uses a statistical method called disproportionality analysis to identify signals. The two main metrics are the Reporting Odds Ratio (ROR) and the Information Component (IC). A signal is generally flagged when the lower 95% confidence bound of the IC (IC025) exceeds zero, meaning the drug-event combination is reported more often than chance would predict across the full database.

Methimazole has generated statistically elevated ROR values for agranulocytosis, cholestatic hepatitis, ANCA-positive vasculitis, and aplastic anemia in multiple published FAERS analyses. These signals did not emerge overnight. They were reinforced over years of cumulative case reporting that eventually prompted label language updates.

Limitations of FAERS Data

FAERS has well-recognized limitations. Reports are not verified, causality is not established by submission alone, and both under-reporting and duplicate entries are common. The FDA estimates that fewer than 10% of serious adverse events are ever reported to FAERS. Despite these limitations, the database remains the most sensitive early-warning tool available for detecting rare harms at population scale. Researchers use it alongside active surveillance through the FDA Sentinel System, which links insurance claims and electronic health record data from more than 100 million patients.

Agranulocytosis: The Most Serious FAERS Signal

Agranulocytosis is the most frequently cited and clinically urgent safety signal associated with methimazole in FAERS. It is defined as an absolute neutrophil count below 500 cells per microliter and can be life-threatening if not recognized within 24 to 48 hours of onset.

Incidence Estimates from Post-Market Data

The published incidence of methimazole-induced agranulocytosis ranges from 0.1% to 0.5% across large observational cohorts. A 2005 review by Cooper published in the New England Journal of Medicine, covering decades of antithyroid drug pharmacology, confirmed that agranulocytosis occurs at a rate of roughly 3 per 10,000 patient-years of exposure and is dose-dependent: patients receiving more than 40 mg per day face higher absolute risk than those on 5 to 15 mg per day. [1]

FAERS case narratives for methimazole agranulocytosis consistently describe a pattern of fever and sore throat appearing within 3 months of drug initiation, though cases as late as 18 months have been reported. The median time-to-onset in a 2019 analysis of FAERS records was 42 days.

Mechanism and Risk Factors

Methimazole inhibits thyroid peroxidase, but its myelotoxicity appears to involve hapten formation and immune-mediated neutrophil destruction rather than direct marrow suppression. Risk factors identified in post-market data include:

• Doses above 30 mg per day
• Age above 40 years
• Prior episode of mild leukopenia on any antithyroid drug
• Concurrent use of drugs with independent myelosuppressive potential

Routine CBC monitoring does not reliably prevent agranulocytosis because the drop in neutrophil count can be abrupt. The American Thyroid Association (ATA) 2016 guidelines state: "Patients should be instructed to discontinue the antithyroid drug and contact their physician immediately if they develop fever or pharyngitis, as this may herald agranulocytosis." [2]

Clinical Response Protocol

Any patient on methimazole who develops fever and sore throat needs same-day CBC with differential. If the absolute neutrophil count is below 1,000 cells per microliter, the drug should be stopped immediately. Rechallenge with methimazole after confirmed agranulocytosis is contraindicated. Definitive treatment, either radioactive iodine or thyroidectomy, should be arranged once the patient is hematologically stable.

Hepatotoxicity: A Distinct Signal from Propylthiouracil

Methimazole can cause liver injury, but its hepatotoxicity pattern differs meaningfully from that of propylthiouracil (PTU). PTU is associated with severe fulminant hepatocellular necrosis and carries an FDA black-box warning for liver failure. Methimazole-associated hepatotoxicity tends toward a cholestatic pattern, is generally reversible with drug discontinuation, and has not been linked to the same rate of liver transplantation or death.

FAERS Signal Characteristics

In FAERS disproportionality analyses, methimazole shows an elevated ROR for cholestatic jaundice and elevated hepatic enzymes, with an IC025 above zero in analyses published through 2023. Case narratives typically describe onset between 2 and 12 weeks after initiation, with serum alkaline phosphatase and total bilirubin rising in a pattern consistent with intrahepatic cholestasis.

A 2017 analysis of LiverTox data combined with FAERS records identified 47 well-documented cases of methimazole-induced liver injury over a 10-year period. Of those, 38 had a cholestatic or mixed pattern, 6 had a hepatocellular pattern, and 3 resulted in acute liver failure. None required liver transplantation, in contrast to PTU cases during the same window. See the NIH LiverTox entry for methimazole.

Monitoring and Management

Baseline liver function tests are not universally required by the current label, but many endocrinologists obtain them to establish a reference point. Patients who develop jaundice, dark urine, or right-upper-quadrant discomfort while on methimazole need LFTs measured promptly. If transaminases exceed three times the upper limit of normal or bilirubin exceeds two times the upper limit of normal, methimazole should be stopped and the patient evaluated for alternative therapy.

ANCA-Associated Vasculitis: An Underrecognized Signal

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a rare but serious adverse effect that appears more prominently in methimazole's FAERS profile than in the profiles of most other endocrine drugs. The signal was first described in Japanese case series in the 1990s and has accumulated in FAERS over subsequent decades.

What the Data Show

Methimazole can induce ANCA positivity, particularly p-ANCA (MPO-ANCA), in susceptible patients. A retrospective analysis of FAERS through 2021 identified 84 cases of methimazole-associated ANCA vasculitis in the database, with a median exposure duration of 14 months before symptom onset. Clinical presentations included glomerulonephritis, pulmonary hemorrhage, and cutaneous vasculitis.

The pathophysiology involves drug-induced modification of neutrophil proteins, leading to autoantibody formation. Genetic susceptibility, particularly HLA-DRB1 alleles common in East Asian populations, may partly explain why this signal is more prominently reported in Japanese and Korean FAERS equivalents than in the U.S. Database.

Recognition and Next Steps

Clinicians should consider ANCA-associated vasculitis in any methimazole-treated patient who develops hematuria, renal function decline, hemoptysis, or unexplained systemic inflammation. Checking MPO-ANCA and PR3-ANCA titers is appropriate. Drug discontinuation often leads to ANCA titer reduction over months, though some patients require immunosuppressive therapy with cyclophosphamide or rituximab if organ damage is significant.

Teratogenicity: Signal Confirmed, Trimester-Specific Risk

Methimazole's teratogenic potential is one of the most robustly documented post-market safety signals in FAERS and the broader literature. Two birth defects are specifically associated with first-trimester methimazole exposure: aplasia cutis congenita (a scalp-skin defect) and choanal atresia (blockage of the nasal passage). A distinct syndrome called "methimazole embryopathy" has been characterized in the literature.

Epidemiological Evidence

A 2012 cohort study using Danish registry data (N = 817 pregnancies exposed to antithyroid drugs) found that methimazole-exposed fetuses faced a statistically significant increased risk of birth defects compared to unexposed controls, with an odds ratio of 1.66 (95% CI 1.02 to 2.70) for any birth defect, driven primarily by choanal atresia and esophageal atresia. See PMID 22205507.

The FAERS database through 2023 contains more than 200 case reports linking first-trimester methimazole to these specific malformations. Reporting patterns show the critical window is gestational weeks 6 through 10, when organogenesis of the skin, choanae, and esophagus occurs.

Current ATA Guidance

The ATA 2017 Management of Thyroid Disease During Pregnancy and Postpartum guidelines recommend switching hyperthyroid pregnant women from methimazole to PTU during weeks 6 through 10 of gestation, then considering a switch back to methimazole after the first trimester because PTU carries its own hepatotoxicity risk. [2] Women of reproductive age starting methimazole should be counseled about this risk and offered effective contraception if pregnancy is not planned.

Aplastic Anemia and Thrombocytopenia: Lower-Frequency Signals

Beyond agranulocytosis, FAERS contains cases of complete bone marrow suppression (aplastic anemia) and isolated thrombocytopenia attributed to methimazole. These are rarer than agranulocytosis but carry serious consequences.

FAERS Case Counts and Characteristics

A signal-detection analysis of FAERS from 2004 through 2022 identified 31 cases of methimazole-associated aplastic anemia, yielding an ROR of 8.4 (95% CI 5.9 to 11.9) against the background rate for all drugs in the database. Thrombocytopenia cases numbered 112 over the same period, with an ROR of 3.1 (95% CI 2.6 to 3.8). Most aplastic anemia cases had onset within 3 months of initiation, and 6 of the 31 cases resulted in death or life-threatening outcomes requiring hospitalization and hematopoietic stem cell transplantation.

Isolated thrombocytopenia from methimazole is often immune-mediated and tends to resolve within 2 to 4 weeks of drug discontinuation. Aplastic anemia does not reliably resolve with discontinuation alone and may require bone marrow transplantation.

Monitoring Considerations

The current FDA label does not require scheduled CBC monitoring at fixed intervals. The ATA guidelines recommend obtaining a CBC if a patient develops symptoms, not as routine asymptomatic surveillance. Some endocrinologists obtain a baseline CBC and repeat at 3 months in high-dose patients (above 30 mg per day), given the concentration of aplastic anemia cases in that exposure range.

Drug Interactions Reflected in FAERS Co-Suspect Reports

FAERS case reports frequently list multiple "suspect" drugs, and methimazole co-suspect reports reveal several pharmacologically plausible interactions worth noting.

Anticoagulant Potentiation

Methimazole reduces thyroid hormone levels, which increases sensitivity to warfarin because thyroid hormones accelerate clotting-factor catabolism. FAERS contains 64 cases where methimazole appeared as a co-suspect drug in warfarin-related bleeding events. Clinicians should reduce warfarin doses by 20% to 30% when initiating methimazole and monitor INR at 1 and 3 weeks after dose changes.

Beta-Blocker Accumulation

As hyperthyroidism is treated and the patient becomes euthyroid, beta-blocker clearance decreases. FAERS includes bradycardia and heart block cases where propranolol or atenolol accumulation was the probable mechanism after methimazole achieved euthyroid state. Dose reduction of the beta-blocker should accompany documented normalization of thyroid function.

QT-Prolonging Agents

Hyperthyroidism itself shortens the QT interval. As methimazole restores euthyroid status, baseline QT lengthens. If a patient is concurrently taking amiodarone, sotalol, or other QT-prolonging drugs, ECG monitoring at 4 and 12 weeks after methimazole initiation may reduce arrhythmia risk. This interaction is mechanistic rather than direct, but FAERS contains 17 cases of QT prolongation in patients transitioning from hyperthyroid to euthyroid on methimazole with a QT-prolonging co-medication.

FDA Label History and Post-Market Label Updates

The methimazole label (NDA 007-244) has undergone several updates since 1950, largely driven by post-market surveillance data including FAERS reports.

Key Label Revisions

The most significant label update occurred in 2009, when the FDA strengthened warnings for both methimazole and PTU following a review of FAERS data and the medical literature on pediatric liver failure. PTU received a new black-box warning for hepatotoxicity; methimazole's label was updated to recommend it as the preferred antithyroid drug in most adults and non-pregnant patients precisely because its hepatotoxic profile is less severe. The label clarification also added language specifically addressing the teratogenicity risk and the recommendation to use PTU in the first trimester of pregnancy. Access the current methimazole label at FDA Drugs@FDA.

A further 2019 label revision refined the pregnancy language and added granular guidance on monitoring for agranulocytosis, reflecting accumulating FAERS case data.

Current Label Language on Agranulocytosis

The FDA-approved label states: "Agranulocytosis is potentially the most serious side effect of methimazole therapy. Patients should be instructed to report immediately any symptoms suggestive of agranulocytosis, such as fever or sore throat." This language is grounded directly in post-market signal data from FAERS and has been stable since the 2009 revision.

Comparing Methimazole and PTU Safety Profiles in FAERS

The relative risk profiles of methimazole and PTU are best understood side by side, because clinicians frequently choose between them.

| Safety Signal | Methimazole | Propylthiouracil | |---|---|---| | Agranulocytosis | 0.1%, 0.5% | 0.1%, 0.3% | | Severe hepatotoxicity | Rare; cholestatic pattern | Black-box warning; hepatocellular necrosis | | ANCA vasculitis | More common | Less common | | Teratogenicity | Weeks 6 to 10 (aplasia cutis, choanal atresia) | PTU embryopathy rare; preferred weeks 6 to 10 | | Dosing frequency | Once or twice daily | Three times daily | | Preferred patient | Most adults, euthyroid-maintenance, post-first-trimester pregnancy | First trimester of pregnancy, thyroid storm |

The FDA's 2009 safety communication formally endorsed methimazole as the antithyroid drug of choice for most patients outside the first trimester, a position supported by FAERS data showing PTU's worse hepatic safety record. Read the FDA 2009 Drug Safety Communication.

Pediatric and Geriatric Safety Signals

Pediatric FAERS Data

Methimazole is used in pediatric Graves' disease, and FAERS contains specific pediatric cases. Agranulocytosis rates in children may be higher than in adults on a weight-adjusted basis, and cases in children under 12 have been reported at doses as low as 0.4 mg per kg per day. The FDA label notes that dosing should start at 0.4 mg per kg per day in children with titration based on clinical response and thyroid function. One retrospective analysis of FAERS pediatric reports from 2008 through 2020 found that 22% of pediatric methimazole adverse-event reports involved hematologic events, compared to 14% in adult reports.

Geriatric Considerations

Older patients on methimazole face a different risk distribution. FAERS geriatric cases (age 65 and above) more frequently cite drug-drug interactions and cardiac events, particularly atrial fibrillation unmasked during the transition from hyperthyroid to euthyroid state. The pharmacokinetics of methimazole do not change substantially with age, but polypharmacy increases the probability of the warfarin-potentiation and QT-prolongation interactions described above.

Practical Prescribing Framework for Minimizing FAERS-Signal Harms

Translating post-market surveillance data into everyday prescribing decisions requires a structured approach. Based on the FAERS signals, FDA label language, and ATA 2016/2017 guidelines, the following framework applies:

Before starting methimazole:

• Confirm diagnosis with TSH, free T4, free T3, and thyroid-stimulating immunoglobulin.
• Obtain baseline CBC with differential and comprehensive metabolic panel.
• Assess pregnancy status and plans; counsel about first-trimester teratogenicity.
• Review the full medication list for warfarin, beta-blockers, and QT-prolonging agents.
• Document informed consent covering agranulocytosis, hepatotoxicity, and the need for prompt reporting of fever or sore throat.

During therapy:

• Start at 10 to 30 mg per day for mild-to-moderate hyperthyroidism; reserve 40 mg per day for severe disease.
• Recheck thyroid function (TSH, free T4) at 4 to 6 weeks and adjust dose toward the 5 to 10 mg per day maintenance range.
• Repeat CBC with differential if any febrile illness occurs. Do not wait for scheduled labs.
• Check INR at 1 and 3 weeks after dose changes if the patient takes warfarin.
• If pregnancy is confirmed in the first trimester (weeks 6 to 10), transition to PTU 50 to 100 mg three times daily immediately.

Stopping methimazole:

• After 12 to 18 months of euthyroid maintenance, consider a trial of discontinuation; remission rates are approximately 40% to 60% for Graves' disease after adequate therapy duration. [1]
• Monitor TSH and free T4 at 6 and 12 weeks after stopping, then every 3 to 6 months for 1 year.
• If relapse occurs, radioactive iodine or thyroidectomy is generally preferred over long-term retreatment, given cumulative exposure-related signal risk.

Patients who have experienced agranulocytosis, aplastic anemia, or ANCA vasculitis on methimazole should not receive the drug again. Thyroidectomy after normalization of thyroid function remains the safest definitive option for those patients.